Ocular Melanoma News and Research

RSS

Research reveals a candidate drug and biomarker to target uveal melanoma

Findings from an international research study involving Irish and Spanish patients reveal a candidate drug and biomarker that could be used to manage uveal melanoma.

2 Feb 2023

Neurological complications of the SARS-CoV-2 vaccine

In a study published in the latest issue of the journal Neurological Sciences, a team of researchers described a three-patient case series presenting with neurological manifestations after the coronavirus disease 2019 (COVID-19) vaccination, followed by a literature review, to propose hypotheses on how neurological symptoms might develop after vaccination.

24 Jan 2022

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, the world's largest clinical cancer research meeting.

1 Jun 2021

Natural plant compound exploits newly identified Achilles' heel in uveal melanoma

A natural plant compound exploits a newly identified Achilles' heel in a cancer of the eye, uveal melanoma. In human cancer cells growing in the lab, the compound shuts down the overactive signaling that drives uveal melanoma cell growth, according to researchers at Washington University School of Medicine in St. Louis.

6 Sep 2018

Researchers discover natural plant compound that shuts down uveal melanoma cell growth

A natural plant compound exploits a newly identified Achilles' heel in a cancer of the eye, uveal melanoma.

6 Sep 2018

Nearly 50 people present with rare eye cancer - ocular melanoma

At least 50 people have been diagnosed with a rare type of eye cancer called ocular melanoma. They are all residents of two locations - Huntersville, North Carolina, and Auburn, Alabama. The cancer is rare and occurs in only six per 1 million population. The high rate of incidence of this cancer in these two locations has stumped researchers.

2 May 2018

New international research project identifies subtypes of ocular melanoma

A new international research project, involving the University of Liverpool's leading eye cancer research group, has identified specific subtypes of ocular melanoma that will help develop improved management strategies and therapies in the future.

23 Aug 2017

Clinical research trial investigates new treatment approach for early-stage eye melanoma

A first-of-its-kind, potentially groundbreaking new option for treating a form of eye cancer is now in its first phase-1 clinical research trial at Wills Eye Hospital in Philadelphia.

30 Mar 2017

Researchers discover new biomarker that puts patients at higher risk for metastasis of uveal melanoma

A study by J. William Harbour, M.D., associate director for Basic Research and leader of the Eye Cancer Site Disease Group at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and colleagues published today in Clinical Cancer Research details the discovery of a biomarker that puts patients at a higher risk for metastasis of uveal melanoma.

2 Mar 2016

SCCA Proton Therapy Center makes advanced radiation therapy accessible to patients with ocular melanoma

For most the ability to see is often taken for granted. But for the thousands diagnosed with ocular melanoma, the fear of losing their eyesight or even worse, their lives, is an all too real possibility. Ocular melanoma is seen as a rare form of cancer, with approximately two thousand new diagnoses per year.

11 Aug 2015

Delcath Systems achieves record quarterly product revenue in Q2 2015

5 Aug 2015

Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announced today that the U.S. Food and Drug Administration Office of Orphan Products Development has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma.

20 Jul 2015

Immunocore completes $320 million (£205 million) private financing round

Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million (GBP £205 million) private financing round.

16 Jul 2015

More patients experience phantom eye symptoms every day, say University of Liverpool researchers

Researchers from the University of Liverpool have found that approximately half of patients who have an eye removed because of a form of eye cancer experience 'phantom eye syndrome.'

2 Jun 2015

CHEMOSAT treatment of UM patients with hepatic metastases highlighted at ASCO 2015

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that results of a large, European single-center experience of the treatment of uveal melanoma patients with hepatic metastases with the Delcath Hepatic CHEMOSAT® Delivery System, were highlighted in an on-line abstract at the American Society of Clinical Oncology Annual Meeting 2015.

1 Jun 2015

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune diseases, today announced clinical trial data from the Phase I/IIa study of its lead programme IMCgp100, at the American Association for Cancer Research Annual Meeting 2015, in Philadelphia, USA.

20 Apr 2015

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.

7 Apr 2015

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Oraya Therapeutics Inc. announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.

15 Sep 2014

ASTRO issues new Model Policy for proton beam therapy

The American Society for Radiation Oncology (ASTRO) has issued a new Model Policy for proton beam therapy (PBT) that details which cancer diagnoses meet ASTRO's evidence-based standards and should be covered by private insurers and Medicare.

5 Jun 2014

Director of Scheie Eye Institute honored with WIO's Suzanne Veronneau Troutman Award

Joan M. O'Brien, MD, the George E. de Schweinitz and William F. Norris Professor of Ophthalmology, chair of the Department of Ophthalmology and director of the Scheie Eye Institute at the Perelman School of Medicine at the University of Pennsylvania, was recently presented with the Women in Ophthalmology's Suzanne Veronneau Troutman Award.

26 Nov 2013